CXCL9, but Not CXCL10, Promotes CXCR3-dependent Immune-mediated Kidney Disease
Overview
Authors
Affiliations
Chemokines are instrumental in macrophage- and T cell-dependent diseases. The chemokine CCL2 promotes kidney disease in two models of immune-mediated nephritis (MRL-Fas(lpr) mice and the nephrotoxic serum nephritis model), but evidence suggests that multiple chemokines are involved. For identification of additional therapeutic targets for immune-mediated nephritis, chemokine ligands and receptors in CCL2-/- and wild-type (WT) MRL-Fas(lpr) kidneys were profiled. The focus was on intrarenal chemokine ligand/receptor pairs that were highly upregulated downstream of CCL2; the chemokine CXCL10 and its cognate receptor, CXCR3, stood out as potential therapeutic targets. However, renal disease was not suppressed in CXCL10-/- MRL-Fas(lpr) mice, and CXCL10-/- C57BL/6 mice were not protected from nephrotoxic serum nephritis compared with WT mice. Because CXCR3 engages with the ligand CXCL9, CXCR3-/- , CXCL9-/- , and CXCL10-/- B6 mice were compared with WT mice with nephrotoxic serum nephritis. Kidney disease, measured by loss of renal function and histopathology, was suppressed in both CXCR3-/- and CXCL9-/- mice but not in CXCL10-/- mice. With nephrotoxic serum nephritis, CXCR3-/- and CXCL9-/- mice had fewer intrarenal activated T cells and activated macrophages. Both IgG glomerular deposits and antigen-specific IgG in serum were reduced in these mice, suggesting that although CXCR3 and CXCL9 initiate nephritis through cell-mediated events, renal inflammation may be sustained by their regulation of IgG. It is concluded that specific blockade of CXCL9
Immune complex deposition promotes NK cell accumulation in the kidney.
De la Cruz A, Garces M, Larios E, Madera-Salcedo I, Crispin J, Rosetti F PLoS One. 2024; 19(11):e0312141.
PMID: 39570975 PMC: 11581347. DOI: 10.1371/journal.pone.0312141.
Song Y, Pan S, Tian J, Yu Y, Wang S, Qiu Q Biomedicines. 2024; 12(6).
PMID: 38927347 PMC: 11201226. DOI: 10.3390/biomedicines12061140.
Lu J, Song L, Luan J, Feng Y, Wang Y, Cao X Clin Cosmet Investig Dermatol. 2024; 17:311-327.
PMID: 38327551 PMC: 10847670. DOI: 10.2147/CCID.S451080.
Tan H, Sprangers B Clin Kidney J. 2023; 16(11):1709-1713.
PMID: 37915924 PMC: 10616439. DOI: 10.1093/ckj/sfad205.
Mesenchymal stem cells enhance CCL8 expression by podocytes in lupus-prone MRL.Fas mice.
Kim H, Lee H, Kim K, Ahn G, Kim M, Lee T Sci Rep. 2023; 13(1):13074.
PMID: 37567910 PMC: 10421856. DOI: 10.1038/s41598-023-40346-8.